Study
|
TP
|
TN
|
FP
|
FN
|
SE (%)
|
SP (%)
|
AU (%)
|
PPV (%)
|
NPV (%)
|
---|
Katki 2011 [10]
|
1 226
|
318 093
|
11 415
|
1 084
|
53.12
|
96.51
|
78.41
|
9.72
|
99.71
|
Dillner 2008 [15]
|
242
|
22 883
|
1 031
|
139
|
63.51
|
95.72
|
79.61
|
19.01
|
99.42
|
Castle 2012 [16]
|
136
|
18 190
|
926
|
260
|
34.32
|
95.22
|
64.72
|
12.81
|
98.61
|
Szarewski 2008 [17]
|
256
|
236
|
444
|
17
|
93.81
|
34.72
|
64.22
|
36.61
|
93.32
|
Sørbye 2011 [18]
|
48
|
92
|
77
|
8
|
85.71
|
54.42
|
70.12
|
38.41
|
92.02
|
Total
|
1 908
|
359 494
|
13 893
|
1 508
|
55.9
|
96.3
|
76.1
|
12.1
|
99.6
|
-
TP true positive, TN true negative, FP false positive, FN false negative, SE sensitivity, SP specificity, AU = AUROC = accuracy = (SE+SP)/2, PPV positive predictive value, NPV negative predictive value, ASC-US+ = ASC-US, LSIL, ASC-H and HSIL, CIN2+ = CIN2, CIN3 and cancer
-
1Significantly higher than the average (p<0.05)
-
2Significantly lower than the average (p<0.05)